Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
T- cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LLy) has an
increase in proteins in a specific pathway called the mTOR pathway within the cancer cells.
In cancer cells it can encourage untimely cell growth, cell production, and cell survival.
Everolimus is an inhibitor of the mTOR pathway and can decrease the growth and survival of
cancer cells. It also prevents communication within cells and stops proteins from being made
that may contribute to leukemia. The main purpose of the study is to find the maximum
tolerated dose of everolimus when used together with standard chemotherapy.